natgillin/translations-raw huggingface dataset:
• NOTE: From the fifth week onwards, after you have completed your initiation period, 0.5 mL (corresponding to the usual dose) should be selected in the dose window of the device. 
Od petog tjedna nadalje nakon dovršetka početnog razdoblja, treba odabrati 0,5 ml (odgovara uobičajenoj dozi) u prozorčiću doze uređaja.
Approximately 30% of patients will also experience reactions at the injection site, predominantly mild inflammation or erythema. 
Otprilike 30% bolesnika također će osjetiti reakcije na mjestu injiciranja u vidu blage upale ili eritema.
Thrombotic microangiopathy including thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome* (class label for interferon beta products, see section 4.4), pancytopenia* 
Trombotička mikroangiopatija uključujući trombotičku trombocitopeničku purpuru/hemolitički uremički sindrom* (značajka klase lijekova koji sadrže interferon beta; vidjeti dio 4.4), pancitopenija*
Rebif is a highly purified soluble protein that is similar to the natural interferon beta that is produced in the human body. 
Rebif je visoko pročišćeni topivi protein sličan prirodnom interferonu beta kojeg stvara ljudsko tijelo.
• Disorders of the retina (back of the eye) such as inflammation or blood clots with consequent vision disorders (vision disturbances, loss of vision) 
• poremećaj mrežnice (unutarnja ovojnica oka) kao što je upala ili krvni ugrušci koji za posljedicu imaju poremećaje vida (smetnje vida, gubitak vida)
After a single dose, intracellular and serum activity of 2'5'OAS synthetase and serum concentrations of beta-2 microglobulin and neopterin increase within 24 hours, and start to decline within 2 days. 
Nakon primjene jedne doze, intracelularna i serumska aktivnost 2-5A sintetaze te serumske koncentracije beta-2 mikroglobulina i neopterina porastu unutar 24 sata i počinju opadati unutar 2 dana.
The precise incidence of antibodies is as yet uncertain. 
Precizna incidencija protutijela još nije pouzdano utvrđena.
The presence of antibodies has been shown to attenuate the pharmacodynamic response to interferon beta-1a (beta-2 microglobulin and neopterin). 
U prisutnosti protutijela primijećen je atenuirani farmakodinamički odgovor na interferon beta-1a (beta-2 mikroglobulin i neopterin).
These results obtained in a subgroup of patients a posteriori should be interpreted cautiously. 
Prilikom tumačenja a posteriori kasnije dobivenih rezultata u podgrupama bolesnika potreban je oprez.
Only clear to opalescent solution without particles and without visible signs of deterioration should be used. 
Treba koristiti samo bistru do opalescentnu otopinu bez čestica i bez vidljivih znakova kvarenja.
The safety and efficacy of Rebif has been evaluated in patients with relapsing-remitting multiple sclerosis at doses ranging from 11 to 44 micrograms (3-12 million IU), administered subcutaneously three times per week. 
Sigurnost i djelotvornost Rebifa procjenjivana je kod bolesnika s relapsno remitirajućom multiplom sklerozom s dozama u rasponu od 11 do 44 mikrograma (3-12 milijuna IU), primijenjenim supkutano, tri puta tjedno.
These symptoms are usually mild, are more common at the start of the treatment and decrease with continued use. 
Ovi simptomi su obično blagi, češći na početku, a smanjuju se tijekom liječenja.
• if you are allergic to natural or recombinant interferon beta or any of the other ingredients of this medicine (listed in section 6). 
• ako ste alergični na prirodni ili rekombinantni interferon beta ili neki drugi sastojak ovog lijeka
If you stop using Rebif 
Ako prestanete primjenjivati Rebif
HOW TO USE REBIF PRE-FILLED PEN (RebiDose) 
KAKO KORISTITI REBIF NAPUNJENU BRIZGALICU (RebiDose)
If you experience troubling local reactions, contact your doctor. 
Ako se pojave neugodne lokalne reakcije, obratite se svom liječniku.
In case of severe or persistent undesirable effects, the dose of Rebif may be temporarily lowered or interrupted, at the discretion of the physician. 
U slučaju težih ili trajnijih nuspojava, prema odluci nadležnog liječnika, doza Rebifa se može privremeno smanjiti ili prekinuti.
Patients should be informed of the most frequent adverse reactions associated with interferon beta administration, including symptoms of the flu-like syndrome (see section 4.8). 
Bolesnike treba upoznati s najčešćim nuspojavama povezanim s primjenom interferona beta, uključujući simptome sindroma sličnog gripi (vidjeti dio 4.8).
The patient may store Rebif at or below 25°C for a single period up to 14 days. 
Bolesnik može čuvati Rebif na ili ispod 25 °C jednokratno u razdoblju od najdulje 14 dana.
Prompt treatment of nephrotic syndrome is required and discontinuation of treatment with Rebif should be considered. 
Nefrotski sindrom potrebno je bez odlaganja liječiti i razmotriti prekid liječenja Rebifom.
• Itching, rash (skin eruptions) 
• svrbež, osip (izbijanje kožnih promjena)
The adverse reactions presented have been identified from clinical studies as well as from postmarketing reports (an asterisk [*] indicates adverse reactions identified during post-marketing surveillance). 
Prikazane nuspojave identificirane su u kliničkim ispitivanjima kao i iz izvješća nakon stavljanja lijeka u promet (zvjezdica [*] označava nuspojave identificirane tijekom praćenja lijeka nakon stavljanja lijeka u promet).
Periodic monitoring of early signs or symptoms, e.g. oedema, proteinuria and impaired renal function is recommended, especially in patients at higher risk of renal disease. 
Preporučuje se povremeno praćenje zbog pojave ranih znakova i simptoma, npr. edema, proteinurije i oštećenja bubrežne funkcije, posebno u bolesnika s povećanim rizikom od bubrežne bolesti.
For the time being there is no well established definition of a high risk patient, although a more conservative approach is to accept at least nine T2 hyperintense lesions on the initial scan and at least one new T2 or one new Gd-enhancing lesion on a follow-up scan taken at least 1 month after the initial scan. 
Za sada nema dobro utvrđene definicije visokorizičnog bolesnika, iako je konzervativniji pristup prihvaćanje barem devet T2 hiperintenzivnih lezija na početnom snimanju i barem jedne nove T2 lezije ili jedne nove Gd-pozitivne lezije na kontrolnom snimanju barem mjesec dana nakon početnog snimanja.
When first starting treatment with Rebif, in order to allow tachyphylaxis to develop thus reducing adverse reactions, it is recommended that patients be started at 8.8 micrograms dose subcutaneously and the dose be increased over a 4 week period to the targeted dose, according to the following schedule: 
Kada započinju liječenje Rebifom, da bi se razvila tahifilaksija i da bi se umanjile nuspojave, preporučuje se da bolesnici počnu s dozom od 8,8 mikrograma supkutano, a potom se doza treba povećavati tijekom razdoblja od 4 tjedna do ciljane doze prema sljedećem rasporedu:
• Hold RebiSlide firmly and slide the release button which is on the side of the device. 
• Čvrsto držite RebiSlide i gurajte gumb za otpuštanje koji se nalazi na bočnoj strani uređaja.
This lower dose is recommended for patients who cannot tolerate the higher dose. 
Ova niža doza preporučuje se za bolesnike koji ne podnose višu dozu.
Subcutaneous and intramuscular administrations of Rebif produce equivalent exposure to interferon beta. 
Supkutana i intramuskularna primjena Rebifa dovodi do jednakovrijednog izlaganja interferonu beta.
• Choose an injection site. 
• Izaberite mjesto injiciranja.
Injection site necrosis, injection site mass, injection site abscess, injection site infections*, increased sweating* 
Nekroza na mjestu injekcije, masa na mjestu injiciranja, apsces na mjestu injiciranja, infekcije na mjestu injiciranja*, pojačano znojenje*
Interferons have been reported to reduce the activity of hepatic cytochrome P450-dependent enzymes in humans and animals. 
Utvrđeno je da interferoni kod ljudi i životinja reduciraju aktivnost jetrenih enzima ovisnih o citokromu P450.
If you forget to use Rebif 
Ako ste zaboravili primijeniti Rebif
The majority of adverse reactions observed with interferon beta-1a are usually mild and reversible, and respond well to dose reductions. 
Većina nuspojava uočenih pri primjeni interferona beta-1a obično su blage i reverzibilne i povlače se nakon smanjenja doze.
• Remove and discard the needle according to the instruction manual provided with your device. 
• Uklonite i odbacite iglu u skladu s priručnikom s uputama koji se isporučuje s Vašim uređajem.
In a 3-year study in patients with secondary progressive multiple sclerosis (EDSS 3-6.5) with evidence of clinical progression in the preceding two years and who had not experienced relapses in the preceding 8 weeks, Rebif had no significant effect on progression of disability, but relapse rate was reduced by approximately 30%. 
U trogodišnjem ispitivanju provedenom kod bolesnika sa sekundarnom progresivnom multiplom sklerozom (EDSS 3-6,5) s pokazateljima kliničke progresije u prethodne dvije godine te kod kojih nije bilo relapsa u prethodnih 8 tjedana, Rebif nije pokazao značajan učinak na napredovanje onesposobljenosti, ali je broj relapsa bio smanjen za približno 30%.
Rebif can be used during breastfeeding. 
Rebif se može primjenjivati tijekom dojenja.
These changes in the thyroid activity are almost always not felt by the patient as symptoms; however your doctor may recommend testing as appropriate. 
U većini slučajeva, bolesnik ne osjeća simptome promjene rada štitnjače, međutim, liječnik može preporučiti odgovarajuće pretrage.
In healthy volunteers after intravenous administration, interferon beta-1a exhibits a sharp multi-exponential decline, with serum levels proportional to the dose. 
Nakon intravenske primjene u zdravih dobrovoljaca, interferon beta-1a pokazuje naglo multieksponencijalno opadanje uz razine u serumu proporcionalne dozi.
If a second clinical demyelinating event occurred confirming definite multiple sclerosis, patients switched to the recommended posology of Rebif 44 micrograms three times per week in an open label manner, while maintaining blinding as to initial randomisation. 
Ako se pojavi drugi klinički događaj demijelinizacije koji definitivno potvrđuje jasnu multiplu sklerozu, bolesnici prelaze na preporučeno doziranje lijeka Rebif od 44 mikrograma tri puta tjedno kao u otvorenom kliničkom ispitivanju, dok istovremeno ostaju maskirani za početnu randomizaciju.
Patients were randomised in a double-blind manner to either Rebif 44 micrograms given three times per week, Rebif 44 micrograms once weekly, or placebo. 
Bolesnici su bili randomizirani na dvostruko slijepi način na Rebif 44 mikrograma tri puta tjedno, Rebif 44 mikrograma jednom tjedno ili na placebo.
Your doctor has prescribed you a lower dose of 22 micrograms (6 million IU) given three times per week. 
Vaš liječnik propisao Vam je nižu dozu od 22 mikrograma (6 milijuna IU) koja se daje tri puta tjedno.
Frequency not known: Transient neurological symptoms (i.e. hypoesthesia, muscle spasm, paraesthesia, difficulty in walking, musculoskeletal stiffness) that may mimic multiple sclerosis exacerbations* 
Prolazni neurološki simptomi (primjerice, hipoestezija, spazam mišića, parestezija, poteškoće u hodanju, ukočenost mišića i kostiju) koji mogu imitirati simptome pogoršanja multiple skleroze*
Rebif (interferon beta-1a) shares the same amino acid sequence with endogenous human interferon beta. 
Rebif (interferon beta-1a) se sastoji od istog slijeda aminokiselina kao i endogeni humani interferon beta.
Over 4 years, the reduction in the mean exacerbation rate was 22% in patients treated with Rebif 22 micrograms, and 29% in patients treated with Rebif 44 micrograms group compared with a group of patients treated with placebo for 2 years and then either Rebif 22 or Rebif 44 micrograms for 2 years. 
Tijekom 4 godine, smanjenje srednje vrijednosti stope egzacerbacija u grupi bolesnika liječenih s Rebifom 22 mikrograma bilo je 22%, odnosno 29% u grupi bolesnika liječenih s Rebifom 44 mikrograma u usporedbi s grupom bolesnika koji su primali placebo 2 godine i nakon toga 2 godine nastavili primati Rebif 22 ili Rebif 44 mikrograma.
Clear to opalescent solution, with pH 3.7 to 4.1 and osmolarity 250 to 450 mOsm/L. 
Bistra do opalescentna otopina, uz pH 3,7 do 4,1 i osmolarnost 250 do 450 mOsm/l.
You should discuss this with your doctor if you are concerned. 
Ako ste zabrinuti, razgovarajte o tome sa svojim liječnikom.
Injection site cellulitis* 
Celulitis na mjestu injiciranja*
It is recommended that you keep track of and rotate your injection sites, so that one area is not injected too frequently in order to minimise the risk of injection site necrosis. 
Preporučuje se da pratite gdje injicirate te mijenjate mjesto injiciranja kako bi se izbjeglo previše često injiciranje na jednom području i smanjio rizik od oštećenja tkiva (nekroza) na mjestu injiciranja.
This medicine is for multidose use. 
Ovaj lijek je za višedoznu primjenu.
Titration dose for Rebif 44 micrograms three times per week (tiw) 
Titracija doze za Rebif 44 mikrograma tri puta tjedno
Clear to opalescent solution, with pH 3.5 to 4.5 and osmolarity 250 to 450 mOsm/L. 
Bistra do opalescentna otopina, uz pH 3,5 do 4,5 i osmolarnost 250 do 450 mOsm/l.
Marketing Authorisation Holder Merck Europe B.V. 
Nositelj odobrenja za stavljanje lijeka u promet Merck Europe B.V.
Rebif is administered by subcutaneous injection. 
Rebif se primjenjuje supkutanom injekcijom.
• Injection site reactions including redness, swelling, discoloration, inflammation, pain and skin breakdown are very common. 
• Reakcije na mjestu injiciranja, a koje uključuju crvenilo, oticanje promjenu boje, upalu, bol i propadanje kože su vrlo česte.
No information is available on the effects of the interferon beta-1a on male fertility. 
Nema podataka o djelovanju interferona beta-1a na plodnost muškaraca.
Diarrhoea, vomiting, nausea Skin and subcutaneous tissue disorders Common: 
Proljev, povraćanje, mučnina Poremećaji kože i potkožnog tkiva Često:
It may cause toxic reactions and allergic reactions in infants and children up to 3 years old. 
Može uzrokovati toksične reakcije i alergijske reakcije u dojenčadi i djece do 3 godine starosti.
• When you do this please read carefully and follow the “RebiDose Instructions for Use” provided separately in the booklet. 
• Kada to učinite, pozorno pročitajte „Upute za upotrebu uređaja RebiDose“ koje se nalaze zasebno u brošuri te ih se pridržavajte.
If you are uncertain about the benefits, please consult your doctor. 
Ako niste sigurni u korisnost lijeka, obratite se svom liječniku.
(UPPER FLAP) 6 pre-filled pens RebiDose 
(GORNJI PREKLOP) 6 napunjenih brizgalica RebiDose
Primary progressive multiple sclerosis 
Primarna progresivna multipla skleroza
Injection site necrosis (ISN) has been reported in patients using Rebif (see section 4.8). 
Nekroza na mjestu injiciranja opisana je kod bolesnika koji primaju Rebif (vidjeti dio 4.8).
The first injection(s) must be performed under the supervision of an appropriately qualified healthcare professional. 
Davanje prve injekcije mora se provesti pod nadzorom odgovarajuće osposobljenog zdravstvenog djelatnika.
• Place RebiSmart at a right angle (90°) to the skin. 
• Položite RebiSmart pod pravim kutom (90°) na kožu.
No interaction studies have been performed with interferon beta-1a in humans. 
Nisu provedena ispitivanja interakcija s interferonom beta-1a kod ljudi.
The proportion of patients with disability progression, as defined by at least one point increase in EDSS confirmed three months later, was reduced from 39% (placebo) to 27% (Rebif 44 micrograms). 
Udio bolesnika s napredovanjem onesposobljenosti utvrđenim povećanjem od barem jednog boda na ljestvici stanja širenja onesposobljenosti (Expanded Disability Status Scale, EDSS) potvrđenim 3 mjeseca kasnije smanjen je s 39% (placebo) na 27% (Rebif 44 mikrograma).
Rebif is available in packs of 1, 3 and 12 pre-filled pens (RebiDose). 
Rebif je dostupan u pakiranjima od 1, 3 i 12 napunjenih brizgalica (RebiDose).
INFORMATION IN BRAILLE rebif 8.8/0.1 / 22/0.25 
16. PODACI NA BRAILLEOVOM PISMU rebif 8,8/0,1 / 22/0,25
• a dry cotton ball or gauze 
• Suhi jastučić vatie ili gaza
Pack sizes of 1, 3 or 12 pre-filled pens. 
Veličine pakiranja od 1, 3 ili 12 napunjenih brizgalica.
For administration of Rebif with RebiDose, the instructions provided in the package leaflet should be followed. 
Za primjenu lijeka Rebif s uređajem RebiDose treba se pridržavati uputa dobivenih u uputi o lijeku.
Pack size of 4 or 12 cartridges. 
Veličina pakiranja od 4 ili 12 uložaka.
• Blood clots in the small blood vessels may occur during your treatment. 
• Tijekom liječenja mogu se pojaviti krvni ugrušci u malim krvnim žilama.
(UPPER FLAP) 
(GORNJI PREKLOP)
Time to peak concentrations following a single subcutaneous injection were 24 to 48 hours for neopterin, beta-2-microglobulin and 2'5'OAS, 12 hours for MX1 and 24 hours for OAS1 and OAS2 gene expression. 
Vrijeme potrebno za postizanje vršne koncentracije neopterina, beta-2 mikroglobulina i 2',5'-oligoadenilat-sintetaze nakon jedne supkutane injekcije bilo je 24 do 48 sati, 12 sati za MX1 te 24 sata za ekspresiju gena OAS1 i OAS2.
• Muscle and joints pain 
• bol u mišićima i zglobovima
• The active substance is interferon beta-1a. 
• Djelatna tvar je interferon beta-1a.
Retinal vascular disorders (i.e. retinopathy, cotton wool spots, obstruction of retinal artery or vein)* 
Poremećaji krvnih žila mrežnice (primjerice, retinopatija, pamučaste mrlje, opstrukciju arterije ili vene mrežnice)*
Rebif is indicated for the treatment of relapsing multiple sclerosis. 
Rebif je indiciran za liječenje relapsnih oblika multiple skleroze.
Other forms of multiple sclerosis 
Drugi oblici multiple skleroze
The device (RebiSmart or RebiSlide) containing a pre-filled cartridge of Rebif must be stored in the device storage box in a refrigerator (2°C - 8°C). 
Uređaj (RebiSmart ili RebiSlide) koji sadrži napunjeni uložak s lijekom Rebif mora se čuvati u kutiji za čuvanje uređaja u hladnjaku (2 °C-8 °C).
For administration, the instructions provided in the package leaflet and in the instruction manual (Instructions for Use) provided with RebiSmart and RebiSlide should be followed. 
Za primjenu lijeka treba se pridržavati uputa u Uputi o lijeku i u priručniku za primjenu (Upute za upotrebu) koje se isporučuju uz uređaje RebiSmart i RebiSlide.
The proportion of patients with disability progression, as defined by at least one point increase in EDSS confirmed three months later, was reduced from 39% (placebo) to 30% (Rebif 22 micrograms). 
Udio bolesnika s napredovanjem onesposobljenosti utvrđenim povećanjem od barem jednog boda na ljestvici stanja širenja onesposobljenosti (Expanded Disability Status Scale, EDSS) potvrđenim 3 mjeseca kasnije smanjen je s 39% (placebo) na 30% (Rebif 22 mikrograma).
• 1st and 2nd week rd and 4 
• 1. i 2. tjedan
Symptoms may include muscle pain, joint pain and swelling, and rash. 
Simptomi mogu uključivati bol u mišićima i u zglobovima, oticanje i osip.
Pruritus, rash, erythematous rash, maculo-papular rash, alopecia* 
Pruritus, osip, eritematozni osip, makulopapularni osip, alopecija*
• patients with relapsing multiple sclerosis. 
• bolesnici s relapsnom multiplom sklerozom.
The posology for patients who have experienced a first demyelinating event is 44 micrograms of Rebif given three times per week by subcutaneous injection. 
Doziranje za bolesnike koji su doživjeli prvi događaj demijelinizacije je 44 mikrograma Rebifa tri puta tjedno supkutanom injekcijom.
Rebif solution for subcutaneous injection in a cartridge is intended for multidose use with either the RebiSmart electronic injection device or the RebiSlide manual pen-injector device following adequate training of the patient and/or carer. 
Otopina lijeka Rebif za supkutanu injekciju u ulošku namijenjena je za višedoznu primjenu i može se primijeniti bilo pomoću elektronskog uređaja za injiciranje RebiSmart ili ručnim uređajem s brizgalicom s injektorom RebiSlide nakon odgovarajuće obuke bolesnika i/ili njegovatelja.
Acetic acid for pH adjustment Sodium hydroxide for pH adjustment Water for injections 
L-metionin benzilni alkohol natrijev acetat acetatna kiselina za podešavanje pH natrijev hidroksid za podešavanje pH voda za injekcije
(LOWER FLAP) 6 pre-filled pens RebiDose 
(DONJI PREKLOP) 6 napunjenih brizgalica RebiDose
Severe elevations in transaminases 
Snažan porast transaminaza
Cases of nephrotic syndrome with different underlying nephropathies including collapsing focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), membranoproliferative glomerulonephritis (MPGN) and membranous glomerulopathy (MGN) have been reported during treatment with interferon-beta products. 
Tijekom liječenja interferonima beta zabilježeni su slučajevi nefrotskog sindroma s različitim podležećim nefropatijama uključujući kolabirajući oblik fokalne segmentalne glomeruloskleroze (FSGS), bolest minimalnih promjena (MCD), membranoproliferativni glomerulonefritis (MPGN) i membransku glomerulopatiju (MGN).
Mannitol, poloxamer 188, L-methionine, benzyl alcohol, sodium acetate, acetic acid and sodium hydroxide for pH adjustment and water for injections. 
Manitol, poloksamer 188, L-metionin, benzilni alkohol, natrijev acetat, acetatna kiselina i natrijev hidroksid za podešavanje pH i voda za injekcije.
The overall incidence of these is slightly higher with Rebif 44 than Rebif 22 micrograms. 
Ukupna incidencija ove pojave je nešto viša kod Rebif 44 mikrograma nego kod Rebif 22 mikrograma.
The solution for injection in a pre-filled syringe is ready for use. 
Otopina za injekciju u napunjenoj brizgalici spremna je za upotrebu.
• NOTE: do not use any areas in which you feel lumps, firm knots, or pain; talk to your doctor or healthcare professional about anything you find. 
• NAPOMENA: nemojte primjenjivati na područjima na kojima osjećate kvržice, tvrde čvorove ili bol: javite svom liječniku ili zdravstvenom djelatniku za takve pojave.
Patients with multiple sclerosis 
Bolesnici s multiplom sklerozom
36 pre-filled syringes. 
36 napunjenih štrcaljki.
The device containing a cartridge of Rebif must be stored in the device storage box in a refrigerator (2°C - 8°C). 
Uređaj koji sadrži uložak napunjen lijekom Rebif mora se čuvati u kutiji za čuvanje uređaja u hladnjaku (2 °C-8 °C).
Treatment is initiated by a gradual increase of the dose (a so-called ‘dose titration') over a period of 4 weeks in order to reduce some of the side effects, it is recommended that: 
Liječenje započinje postupnim porastom doze (takozvana „titracija doze“) tijekom razdoblja od 4 tjedna kako bi se umanjile neke od nuspojava pa se preporučuje:
INFORMATION IN BRAILLE rebif 44/0.5 
16. PODACI NA BRAILLEOVOM PISMU rebif 44/0,5
Rebif 22 micrograms is available as a package of 1, 3, 12, or 36 syringes. 
Rebif 22 mikrograma dostupan je u pakiranju od 1, 3, 12 ili 36 štrcaljki.
Rebif8.8micrograms and Rebif22 micrograms are supplied in an initiation pack that is intended for use during the initial 4 weeks of treatment, during which a gradual increase in Rebif dose is recommended. 
Rebif 8,8 mikrograma i Rebif 22 mikrograma dostupni su u pakiranju za početak liječenja koje je namijenjeno za primjenu tijekom početna 4 tjedna liječenja tijekom kojih se preporučuje postupni porast doze lijeka Rebif.
The pack contains 6 individual doses of 0.2 mL of Rebif 8.8 micrograms solution for injection in a 1 mL type 1 glass syringe with a stainless steel needle and 6 individual doses of 0.5 mL of Rebif 22 micrograms solution for injection in a 1 mL type 1 glass syringe with a stainless steel needle. 
Pakiranje se sastoji od 6 pojedinačnih doza s 0,2 ml otopine za injekciju lijeka Rebif 8,8 mikrograma u staklenoj štrcaljki, staklo tipa I, volumena 1 ml s iglom od nehrđajućeg čelika i 6 pojedinačnih doza s 0,5 ml otopine za injekciju Rebifa 22 mikrograma u staklenoj štrcaljki, staklo tipa I, volumena 1 ml s iglom od nehrđajućeg čelika.